Tenosal

Tenosal is a new compound obtained by esterifying salicylic acid with 2-thiophene-carboxylic acid and displays anti-inflammatory, analgesic and antipyretic properties.

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Tenosal is a new compound obtained by esterifying salicylic acid with 2-thiophene-carboxylic acid and displays anti-inflammatory, analgesic and antipyretic properties. Extraction recovery measured is on average 95.75% for Tenosal, 98.71% for salicylic acid (SA) and 91.11% for TA. In the whole analysis of Tenosal extracted from plasma, the inter-assay coefficient of variation (C.V.) ranges from 1.00 to 5.86% and the intra assay C.V. is 5.01%. The administration of Tenosal allows a higher bioavailability of SA to be achieved than after dosing with ASA[1].

Both sexes of albino Sprague-Dawley rats (175 to 200 g body weight) are used for the experiment. Before the trial the animals are caged for seven days at 21 to 22°C and 55 to 75% relative humidity with a cycle of 12 h light-12 h dark. The animals are orally treated with Tenosal (300 mg/kg) or ASA (220 mg/kg) by a gastric gavage, both substances being suspended in 2% arabic gum. Six animals per group are killed at times 0 (baseline), 0.5, 1, 2, 4, 8, 16 and 24 h. Heparinized blood is sampled and centrifuged to obtain plasma. Liver, kidneys, lungs, myocardium, gastric wall and intestinal wall are also sampled from the animals killed 0, 1, 2, 4, 8 and 16 h after dosing. All the samples are stored in a freezer at -20°C[1].

[1]. Lucarelli C, et al. Evaluation of 2-(2-thiophenecarboxy)benzoic acid and related active metabolites in biological samples. J Chromatogr. 1992 Jan 3;573(1):150-3.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline